BeOne is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,300 employees in China, the United States, Australia and Switzerland, BeOne is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeOne is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeOne markets ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID®(lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.